Theratechnologies explores sale, other options

Theratechnologies has posted a "sale" sign on the company as it announced its intention to conduct a strategic review of its options. At the same time, the Canadian developer said that it is considering raising C$35 million in equity financing to fund its operations. One other point to make on the subject of maximizing shareholder value: Partnership and licensing deals are available for its lead compound--tesamorelin, a late-stage therapy for HIV-associated lipodystrophy.

"Our first Phase III results, as published in the New England Journal of Medicine, indicate that tesamorelin may offer an attractive combination of efficacy and safety with potential advantages over other approaches to treat HIV-associated lipodystrophy," touted CEO Yves Rosconi in a release.

- see this release
- here's the report from Canada East

Suggested Articles

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.

Since Takeda bought out Shire, it’s lost a number of high-ranking research execs from the Irish rare disease biotech; it’s also losing one of its own.

Just a few months after a series B-plus worth $75 million, U.S.-China biotech Harbour BioMed has nabbed a major $102.8 million series C.